Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).

Provencio, M, Nadal, E, Insa, A, Campelo, RG, Casal, J, Dómine, M, Massuti, B, Majem, M, Rodríguez-Abreu, D, Martínez-Marti, A, de Castro, J, de Antonio, DG, Macia, I, Figueroa, S, Vago, LF, Calvo, V, Palmero, R, Sierra-Rodero, B, Martínez-Toledo, C, Molina-Alejandre, M, Serna-Blasco, R, Romero, A, Cruz-Bermúdez, A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11)DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35.900(Q1/1D).

Borque-Fernando, A, Zapatero, A, Manneh, R, Alonso-Gordoa, T, Couñago, F, Domínguez-Esteban, M, López-Valcárcel, M, Rodríguez-Antolín, A, Sala-González, N, Sanmamed, N, Maroto, P. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9)DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1.200(Q3/7D).

Gray, JE, Markovets, A, Reungwetwattana, T, Majem, M, Nogami, N, Peled, N, Lee, JS, Cho, BC, Chewaskulyong, B, John, T, Han, JY, Sebastian, M, Todd, A, Rukazenkov, Y, Barrett, C, Chmielecki, J, Lee, SM, Ramalingam, SS, Hartmaier, R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11)DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20.800(Q1/1D).